Arthritis Research & Therapy | |
Impact of VIP and cAMP on the regulation of TNF-α and IL-10 production: implications for rheumatoid arthritis | |
Richard Williams2  Fionula M Brennan2  Marc Feldmann2  Abhilash Jain1  Salman Ahmed2  Sarah Field2  Andrew D Foey2  | |
[1]Department of Musculoskeletal Surgery, Charing Cross Hospital Campus, Imperial College School of Medicine, London, UK | |
[2]Kennedy Institute of Rheumatology Division, Charing Cross Hospital Campus, Imperial College School of Medicine, London, UK | |
关键词: VIP; TNF-α; T cells; macrophage; IL-10; | |
Others : 1101339 DOI : 10.1186/ar999 |
|
received in 2003-03-14, accepted in 2003-08-11, 发布年份 2003 | |
![]() |
【 摘 要 】
Vasoactive intestinal peptide (VIP) is an anti-inflammatory immunomodulatory neuropeptide with therapeutic potential demonstrated for collagen-induced arthritis. The aim of this study was to characterise its potential anti-arthritic effect on human monocytes, macrophages, T cells, and rheumatoid arthritis synovial membrane cells. Monocytes, macrophages, and T cells derived from human peripheral blood were treated with VIP and compared with other cAMP-elevating drugs for a range of activating stimuli. Cytokine production was assessed for cell cultures and, in addition, the ability of VIPs to activate cAMP response element binding protein. VIP partially suppressed monocyte- and macrophage-derived tumour necrosis factor α (TNF-α) with no effect on IL-10, whereas VIP fails to regulate IL-10 and TNF-α production by T lymphocytes. No such modulation of cytokine profile was observed for rheumatoid arthritis synovial membrane cells. Elevation of intracellular cAMP, on the other hand, potently suppressed macrophage TNF-α production and modulated T-cell response by inhibiting TNF-α and IFN-γ. VIP's lack of effect on IL-10 and its slight effect on TNF-α results from cAMP being rapidly degraded as the phosphodiesterase IV inhibitor, rolipram, rescues cAMP-dependent activation of cAMP response element binding protein. Interestingly, macrophages stimulated with phorbol 12-myristate 13-acetate/ionomycin displayed an augmented IL-10 response upon addition of dibutyryl cAMP, with corresponding downregulation in TNF-α, suggesting a complex interaction between protein kinase C and protein kinase A in cytokine regulation. In conclusion, VIP may represent an efficaceous anti-arthritic treatment modulating macrophage and T-cell cytokine profiles when used alongside a phosphodiesterase inhibitor.
【 授权许可】
2003 Foey et al., licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
20150131124426616.pdf | 447KB | ![]() |
|
Figure 7. | 38KB | Image | ![]() |
Figure 5. | 29KB | Image | ![]() |
Figure 6. | 43KB | Image | ![]() |
Figure 4. | 30KB | Image | ![]() |
Figure 3. | 48KB | Image | ![]() |
Figure 2. | 34KB | Image | ![]() |
Figure 1. | 30KB | Image | ![]() |
【 图 表 】
Figure 1.
Figure 2.
Figure 3.
Figure 4.
Figure 6.
Figure 5.
Figure 7.
【 参考文献 】
- [1]Feldmann M, Brennan FM, Maini RN: Role of cytokines in rheumatoid arthritis. Ann Rev Immunol 1996, 14:397-440.
- [2]Kambayashi T, Jacob CO, Zhou D, Mazurek N, Fong M, Strassmann G: Cyclic nucleotide phosphodiesterase type IV participates in the regulation of IL-10 and in the subsequent inhibition of TNFα and IL-6 release by endotoxin-stimulated macrophages. J Immunol 1995, 155:4909-4916.
- [3]Meisel C, Vogt K, Platzer C, Randow F, Liebenthal C, Volk H-D: Differential regulation of monocytic tumour necrosis factor-a and interleukin-10 expression. Eur J Immunology 1996, 26:1580-1586.
- [4]Ross SE, Williams RO, Mason LJ, Mauri C, Marinova-Mutafchieva L, Malfait A-M, Maini RN, Feldmann M: Suppression of TNFα expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram. J Immunol 1997, 159:6253-6259.
- [5]Nyman U, Mussener A, Larsson E, Lorentzen J, Klareskog L: Amelioration of collagen II-induced arthritis in rats by the type IV phosphodiesterase inhibitor Rolipram. Clin Exp Immunol 1997, 108:415-419.
- [6]Delgado M, Abad C, Martinez C, Leceta J, Gomariz RP: Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med 2001, 7:563-568.
- [7]Williams RO: Therapeutic effect of vasoactive intestinal peptide in collagen-induced arthritis. Arthritis Rheum 2002, 46:271-273.
- [8]Delgado M, Pozo D, Martinez C, Leceta J, Calvo JR, Ganea D, Gomariz RP: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit endotoxin-induced TNFα production by macrophages: in vitro and in vivo studies. J Immunol 1999, 162:2358-2367.
- [9]Delgado M, Martinez C, Pozo D, Calvo JR, Leceta J, Ganea D, Gomariz RP: Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-a and IL-6. J Immunol 1999, 162:1200-1205.
- [10]Delgado M, Munoz-Elias EJ, Kan Y, Gozes I, Fridkin M, Brenneman DE, Gomariz RP, Ganea D: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumour necrosis factor alpha transcriptional activation by regulating nuclear factor-kB and cAMP response element-binding protein/c-Jun. J Biol Chem 1998, 273:31427-31436.
- [11]Martinez C, Delgado M, Pozo D, Leceta J, Calvo JR, Ganea D, Gomariz RP: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide modulate endotoxin-induced IL-6 production by murine peritoneal macrophages. J Leukoc Biol 1998, 63:591-601.
- [12]Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D: VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNgamma synthesis by T cells. J Neuroimmunol 1999, 96:167-181.
- [13]Delgado M, Ganea D: Inhibition of endotoxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in vitro and in vivo. J Immunol 2001, 167:966-975.
- [14]Delgado M, Ganea D: Vasoactive intestinal peptide inhibits IL-8 production in human monocytes. Biochem Biophys Res Commun 2003, 301:825-832.
- [15]Delgado M, Ganea D: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kB and IFN regulatory factor 1 activation. J Immunol 1991, 162:4685-4696.
- [16]Delgado M, Munoz-Elias E, Gomariz RP, Ganea D: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies. J Immunol 1999, 162:1707-1716.
- [17]Delgado M, Ganea D: Cutting edge: is vasoactive intestinal peptide a type 2 cytokine? J Immunol 2001, 166:2907-2912.
- [18]Ganea D: Regulatory effects of vasoactive intestinal peptide on cytokine production in central and peripheral lymphoid organs. Adv Neuroimmunol 1996, 6:61-74.
- [19]Said S: VIP as a modulator of lung inflammation and airway constriction. Am Rev Respir Dis 1991, 143:22-24.
- [20]Pozo D, Delgado M, Martinez C, Guerrero JM, Leceta J, Gomariz RP, Calvo JR: Immunobiology of vasoactive intestinal peptide (VIP). Immunol Today 2000, 21:7-11.
- [21]Abrams J, Roncorolo MG, Yssel H, Andersson U, Gleich GJ, Silver J: Strategies and practice of anti-cytokine monoclonal antibody development: immunoassay of IL-10 and IL-5 in clinical samples. Immunol Rev 1992, 127:5-24.
- [22]Engelberts I, Moller A, Schoen GJ, van der Linden CJ, Buurmann WA: Evaluation of measurement of human TNF in plasma by ELISA. Lymphokine Cytokine Res 1991, 10:69-76.
- [23]Foey AD, Parry SL, Williams LM, Feldmann M, Foxwell BMJ, Brennan FM: Regulation of monocyte IL-10 synthesis by endogenous IL-1 and TNFα: Role of the p38 and p42/44 mitogen-activated protein kinases. J Immunol 1998, 160:920-928.
- [24]Dewitt D, Gourlet P, Amraoui Z, Vertongen P, Willems F, Robberecht P, Goldman M: The vasoactive intestinal peptide analogue RO25-1553 inhibits the production of TNF and IL-12 by LPS-activated monocytes. Immunol Lett 1998, 60:57-60.
- [25]Hernanz A, Tato E, De la Fuente M, de Miguel E, Arnalich F: Differential effects of gastrin-releasing peptide, neuropeptide Y, somatostatin and vasoactive intestinal peptide on interleukin-1 beta, interleukin-6 and tumour necrosis factor-alpha production by whole blood cells from healthy young and old subjects. J Neuroimmunol 1996, 71:25-30.
- [26]Foxwell B, Brown K, Bondeson J, Clarke C, de Martin R, Brennan F, Feldmann M: Efficient adenoviral infection with IkappaB alpha reveals that macrophage tumour necrosis factor alpha production in rheumatoid arthritis is NF-kappaB dependent. Proc Natl Acad Sci USA 1998, 95:8211-8215.